ArticleFrontiers in molecular biosciences2026
FNA-based lipidomics reveals coordinated lipid metabolic remodeling in pancreatic cancer.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor prognosis. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is routinely used for preoperative tissue confirmation; however, its potential for comprehensive lipidomic profiling in a preoperative diagnostic setting remains insufficiently explored. Given the critical role of lipid metabolic reprogramming in PDAC progression, we investigated whether lipidomic alterations could be reliably captured in EUS-FNA-derived specimens. Methods: Paired tumor and adjacent non-tumor tissues obtained via EUS-FNA from 13 PDAC patients were subjected to widely targeted (pseudo-targeted) liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based lipidomic analysis. Differential lipid species were identified through multivariate and univariate analyses. A composite lipid score was constructed based on principal component loadings. Serum samples from an independent cohort of 30 PDAC patients were included for exploratory projection analysis. Results: A total of 1822 lipid species across 47 lipid classes were detected in EUS-FNA-derived specimens. Tumor tissues displayed coordinated lipid alterations, including accumulation of storage lipids and structural remodeling of fatty acyl chains characterized by elongation and increased unsaturation. These alterations were readily detectable in EUS-FNA-derived specimens. These patterns showed a tendency to distinguish tumor from adjacent non-tumor samples within the FNA cohort. Exploratory projection suggested directionally consistent lipid changes in serum samples. Conclusion: Lipid metabolic remodeling in PDAC can be reliably detected in preoperative EUS-FNA-derived specimens. These findings support the feasibility of lipidomic profiling in minimally invasive diagnostic samples and highlight the translational potential of EUS-FNA-based metabolic assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.